Workflow
Esperion(ESPR)
icon
Search documents
ESPR Files New Drug Submissions for Nexletol & Nexlizet in Canada
ZACKS· 2024-12-03 16:10
Esperion Therapeutics, Inc. (ESPR) announced that it has filed new drug submissions (NDSs) in Canada to seek approval for its once-daily, oral non-statin drugs Nexletol (bempedoic acid) and Nexlizet as a treatment to reduce low-density lipoprotein cholesterol or LDL-C (bad cholesterol) and cardiovascular risk.Nexlizet is a combination of bempedoic acid and ezetimibe.Shares of the company were up 10.7% on Dec. 2 following the announcement of the news.ESPR stock has increased 3.6% so far this year against the ...
Esperion Therapeutics: Growth Initiatives Are Paying Off - Buy
Seeking Alpha· 2024-11-13 07:08
I maintain my buy rating on Esperion Therapeutics, Inc.(NASDAQ: ESPR ) given its strong Q3 2024 financial performance, which is a testament to the success of its unique value proposition discussed in my previousI am an experienced financial analyst and a former writer for Fade The Market on Seeking Alpha, with a passion for numbers and a knack for unraveling complex financial data. Armed with a strong financial modeling and data analysis background, I thrive on providing accurate insights and recommendation ...
Esperion(ESPR) - 2024 Q3 - Quarterly Report
2024-11-07 21:22
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35986 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 26-1870780 (State or other jurisdict ...
Esperion(ESPR) - 2024 Q3 - Earnings Call Transcript
2024-11-07 18:35
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q3 2024 Earnings Call November 7, 2024 8:00 AM ET Company Participants Alina Venezia - Director, Investor Relations Sheldon Koenig - President and Chief Executive Officer Ben Halladay - Chief Financial Officer Betty Jean Swartz - Chief Business Officer Eric Warren - Chief Commercial Officer Conference Call Participants Dennis Ding - Jefferies Serge Belanger - Needham Jason Zemansky - Bank of America Lander Egaña-Gorroño - H.C. Wainwright Tom Shrader - BTIG Operator ...
Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y
ZACKS· 2024-11-07 17:00
Esperion Therapeutics, Inc. (ESPR) incurred a loss of 15 cents per share for the third quarter of 2024, which was wider than the Zacks Consensus Estimate of a loss of 14 cents. The company had incurred a loss of 37 cents per share in the year-ago quarter.Esperion generated revenues of $51.6 million, up nearly 52% year over year, driven by higher collaboration revenues and product revenues in the United States. However, the reported figure missed the Zacks Consensus Estimate of $55 million.Shares of Esperion ...
Esperion Therapeutics (ESPR) Reports Q3 Loss, Lags Revenue Estimates
ZACKS· 2024-11-07 13:11
Esperion Therapeutics (ESPR) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.37 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -7.14%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.15 per share when it actually produced a loss of $0.05, delivering a surprise of 66.67%.Over the last four quarters, ...
Esperion(ESPR) - 2024 Q3 - Quarterly Results
2024-11-07 12:22
Exhibit 99.1 Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update – Total Revenue Increased 52% Year-over-Year to $51.6 Million with U.S. Net Product Revenue of $31.1 Million, Representing 53% Growth – – Total Retail Prescription Equivalents Increased 12% and New to Brand Prescriptions Grew 18% from Second Quarter – – October 2024 Total Retail Prescription Equivalents Increased 17% and New to Brand Prescriptions Grew 20% Compared to First Four Weeks of Q3 2024 – – Conference ...
Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update
GlobeNewswire News Room· 2024-11-07 11:00
– Total Revenue Increased 52% Year-over-Year to $51.6 Million with U.S. Net Product Revenue of $31.1 Million, Representing 53% Growth – – Total Retail Prescription Equivalents Increased 12% and New to Brand Prescriptions Grew 18% from Second Quarter – – October 2024 Total Retail Prescription Equivalents Increased 17% and New to Brand Prescriptions Grew 20% Compared to First Four Weeks of Q3 2024 – – Conference Call and Webcast Today at 8:00 a.m. ET – ANN ARBOR, Mich., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Esper ...
Esperion to Participate in Upcoming Jefferies London Healthcare Conference
GlobeNewswire News Room· 2024-11-04 13:00
ANN ARBOR, Mich., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 2024 Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 11:30 a.m. ET. The live webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days. Es ...
Esperion to Report Third Quarter 2024 Financial Results on November 7
GlobeNewswire News Room· 2024-10-24 12:00
ANN ARBOR, Mich., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2024 financial results before the market opens on Thursday, November 7, 2024. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. Please click here to pre-register to participate in the conference call and obtain your dial in number and PIN. A live audio webcast can be accessed on the investor and media sec ...